Skip to main content

Table 3 Hazard ratios for studied end points according to treatment at baseline

From: Effects of oral glucose-lowering drugs on long term outcomes in patients with diabetes mellitus following myocardial infarction not treated with emergent percutaneous coronary intervention - a retrospective nationwide cohort study

Glucose-lowering drug

Cardiovascular mortality

Composite of cardiovascular

mortality and non-fatal MI

All-cause mortality

 

HR

95% CI

HR

95% CI

HR

95% CI

Metformin

1

 

1

 

1

 

Insulin

1.47

1.29-1.68

1.46

1.29-1.66

1.47

1.30-1.66

Glibenclamide

1.31

1.13-1.51

1.34

1.17-1-54

1.26

1.10-1.44

Glimepiride

1.15

1.00-1.33

1.15

1.01-1.32

1.14

1.00-1.31

Glipizide

1.19

1.01-1.40

1.24

1.06-1.44

1.18

1.01-1.37

Gliclazide

1.04

0.83-1.30

1.09

0.89-1.35

1.00

0.81-1.23

Tolbutamide

1.19

1.01-1.40

1.22

1.05-1.43

1.16

0.99-1.35

All sulfonylureas

1.20

1.05-1.37

1.22

1.08-1.38

1.17

1.04-1.32

  1. Hazard ratios (HRs) and 95% confidence intervals (CIs) for adverse cardiovascular end points according to glucose-lowering drug (monotherapy) at baseline. Time-dependent Cox analyses were performed with adjustments for age, sex, socioeconomic status, calendar year, concomitant pharmacotherapy, and comorbidity. MI = Myocardial infarction.
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840